Solutions
Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Inquiry

Perinatal Toxicity Evaluation

Perinatal toxicity evaluation is the third segment of developmental and reproductive toxicology evaluation. Our company employs talented and highly trained toxicologists focused on rare disease drug safety evaluation services, and can provide complete perinatal toxicity evaluation services to accelerate rare disease therapy research and development.

Introduction to Perinatal Toxicity Evaluation

Perinatal toxicity evaluation is used to study the adverse effects of drug administration from embryo implantation to weaning on pregnant/lactating females, as well as on embryonic and offspring development. Due to the possible delay in the effects during this period, the experiment should be continued until the sexual maturity of the offspring.

Methods of Perinatal Toxicity Evaluation

Perinatal toxicity evaluation is generally performed in rats, and experiments are performed by various routes of administration, such as dietary, gavage, etc. The administration period for female animals should be from the closure of the embryonic hard palate to the end of lactation. To detect the adverse effects of drugs that may be used in infants and children, specific circumstances should be considered, direct administration to offspring of specific age groups should be selected, and relevant experimental studies should be conducted.

1-3-2-3-3 Perinatal Toxicity Evaluation-1 Fig.1 Perinatal evaluation of antiretroviral drugs. (Schnoll, Jordan G., et al., 2021)

Our Services

Our company's toxicologists can design preliminary dose ranges and provide you with personalized service, and our experimental animal platforms can meet your diverse research needs. The perinatal toxicity evaluation services we can provide include but are not limited to the following:

  • Design of Perinatal Toxicity Evaluation

Animals Selection

Rodents are provided for experiments, and rats are generally recommended. The number and grouping of animals are designed according to the needs of data analysis.

Dosage Design

Professional toxicologists design the dosing period before the experiment. The dosing period for female animals should generally start from the closure of the embryonic hard palate to the end of lactation.

Observation

Providing observations of physical signs, death, body weight, food intake and other indicators that have been proven to be meaningful in toxicological studies.

Endpoint Analysis

Dissecting adult animals according to customer needs, observe the survival and development of offspring, and performing histological examination if necessary.

  • Content of Perinatal Toxicity Evaluation
  • Study of enhanced toxicity in pregnant animals compared to non-pregnant female animals.
  • Study of prenatal and postnatal mortality in offspring.
  • Study of the growth and development of F1 generation.
  • Functional defect of F1 generation, including behavior, sexual maturation, and reproductive.

Our Advantages

1-3-2-3-3 Perinatal Toxicity Evaluation-3
  • Providing standardized upstream platform solutions
  • Automation-friendly workflow
  • Extensive experience and advanced platforms
  • Careful design and transparent operation process
  • Superior data quality and fast turnaround
  • Timely project reporting and after-sales service

As an integrated CRO, our company employs talented and highly trained scientists who focus on every aspect of rare disease therapy research and development, particularly in perinatal toxicity evaluation. We have the capabilities and resources to provide professional communication and problem-solving support to ensure that we can quickly respond to the changing needs of your rare disease therapy research projects. If you are interested in our services, please feel free to contact us for more information.

Reference

  • Schnoll, Jordan G., et al. "Evaluating neurodevelopmental consequences of perinatal exposure to antiretroviral drugs: current challenges and new approaches." Journal of Neuroimmune Pharmacology 16 (2021): 113-129.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services

Copyright © Protheragen. All rights reserves.